{"version":"1.0","type":"link","title":"A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma.","author_name":"Garralda E 외","author_url":"https://prs-insight.online/author/Garralda%20E","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/94366","thumbnail_width":1200,"thumbnail_height":630}